Evofem Biosciences Analyst Ratings
BenzingaDec 13, 2023 04:20 ET
Evofem Biosciences Analyst Ratings
Benzinga Analyst RatingsOct 13, 2022 05:38 ET
Analysts Offer Insights on Healthcare Companies: Evofem Biosciences (OtherEVFM), Greenwich LifeSciences (GLSI) and Chinook Therapeutics (KDNY)
TipRanksAug 15, 2022 07:00 ET
Evofem Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow JonesAug 15, 2022 06:48 ET
Evofem Biosciences Price Target Raised to $4.00/Share From $2.00 by HC Wainwright & Co.
Dow JonesAug 15, 2022 06:48 ET
Evofem Biosciences analyst ratings
Benzinga Analyst RatingsAug 15, 2022 06:38 ET
HC Wainwright & Co. Maintains Buy on Evofem Biosciences, Raises Price Target to $4
Benzinga Real-time NewsAug 15, 2022 06:38 ET
Evofem Biosciences (EVFM) Receives a Sell from Morgan Stanley
TipRanksJul 15, 2022 12:55 ET
Evofem Biosciences Is Maintained at Underweight by Morgan Stanley
Dow JonesJul 15, 2022 10:37 ET
Evofem Biosciences Price Target Cut to $0.75/Share From $2.00 by Morgan Stanley
Dow JonesJul 15, 2022 10:37 ET
Evofem Biosciences analyst ratings
Benzinga Analyst RatingsJul 15, 2022 10:28 ET
Morgan Stanley Maintains Underweight on Evofem Biosciences, Lowers Price Target to $0.75
Benzinga Real-time NewsJul 15, 2022 10:28 ET
Morgan Stanley Adjusts Price Target for Evofem Biosciences to $0.75 From $2, Maintains Underweight Rating
MT NewswiresJul 14, 2022 16:08 ET
Laidlaw & Co. Initiates Evofem Biosciences at Buy with $3.50 Price Target
MT NewswiresJun 2, 2022 11:35 ET
Evofem Biosciences Price Target Announced at $3.50/Share by Laidlaw & Co.
Dow JonesJun 2, 2022 09:39 ET
Evofem Biosciences Initiated at Buy by Laidlaw & Co.
Dow JonesJun 2, 2022 09:39 ET
Evofem Biosciences analyst ratings
Benzinga Analyst RatingsJun 2, 2022 09:30 ET
Laidlaw & Co. Initiates Coverage On Evofem Biosciences with Buy Rating, Announces Price Target of $3.5
Benzinga Real-time NewsJun 2, 2022 09:30 ET
No Data
No Data